{"product_id":"iccm-pestle-analysis","title":"(ICCM) IceCure Medical Ltd PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis IceCure Medical Ltd PESTLE Analysis explains the company’s cryoablation technology, why it’s valuable for minimally invasive tumor treatment, and how external political, economic, social, technological, legal, and environmental forces affect its prospects. The page shows a real preview\/sample of the report so you can assess style and depth; purchase the full version to receive the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael HQ, 2006\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical was founded in 2006 and is based in Caesarea, Israel, so it operates inside Israel’s security, trade, and regulatory setting. Israel’s GDP was about $540 billion in 2024, while defense spending stayed near 8% of GDP, keeping geopolitical risk high for investors. Regional tensions can affect operations, talent mobility, and market sentiment around Israeli medtech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. FDA access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe U.S. is IceCure Medical Ltd’s key medtech gatekeeper, since FDA clearance or approval controls market entry. IceCure Medical Ltd’s ProSense won FDA De Novo authorization in June 2024 for very low-risk breast cancer, showing how one filing can unlock U.S. sales.\u003c\/p\u003e\n\u003cp\u003eIn medtech, FDA timing can shift launch dates by quarters and delay revenue access.\u003c\/p\u003e\n\u003cp\u003ePolicy or review changes at the FDA can still reshape IceCure Medical Ltd’s U.S. rollout and reimbursement plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU market approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s EU growth hinges on CE-marking under Regulation (EU) 2017\/745, which now governs access across all 27 EU countries. In practice, national reimbursement and hospital procurement can still differ, so the same clearance can move fast in one market and stall in another. Cross-border sales need tight political and regulatory coordination because MDR reviews, local tender rules, and reimbursement timing can change adoption speed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic reimbursement dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBreast tumor cryoablation still depends heavily on public payers, and that makes reimbursement a political gatekeeper for IceCure Medical Ltd. In 2025, Medicare covered about 68 million Americans, so a national coverage call can shape access fast, while public systems in Europe and the UK can decide whether hospitals adopt the procedure at all.\u003c\/p\u003e\n\u003cp\u003eCoverage and payment terms matter because they determine whether doctors can bill the treatment, not just whether they can do it. If payers classify cryoablation as experimental or pay too little, uptake stays narrow; if they back it, use can scale across breast centers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic payers drive access.\u003c\/li\u003e\n\u003cli\u003eCoverage rules shape adoption.\u003c\/li\u003e\n\u003cli\u003ePayment gaps slow hospital use.\u003c\/li\u003e\n\u003cli\u003ePolicy shifts can lift volumes fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeopolitical risk in Israel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIsrael’s security risk stayed elevated in 2025, and rating agency S\u0026amp;P kept Israel at A+ with a negative outlook after the war shock in April 2024. For IceCure Medical Ltd, any escalation can delay clinical visits, limit travel, and disrupt manufacturing or regulators’ access to sites. Diversifying production, suppliers, and trial locations reduces this single-country exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecurity events can halt site access\u003c\/li\u003e\n\u003cli\u003eTravel limits slow trials and audits\u003c\/li\u003e\n\u003cli\u003eManufacturing buffers help continuity\u003c\/li\u003e\n\u003cli\u003eDiversification lowers market risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIceCure Faces Political Risk from Israel Tensions and U.S. FDA Gatekeeping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk for IceCure Medical Ltd is driven by Israel’s security climate and by U.S. and EU health policy. Israel’s defense burden stayed near 8% of GDP in 2024, and war risk can still disrupt staff travel, site access, and supply chains.\u003c\/p\u003e\n\u003cp\u003eIn the U.S., FDA decisions are the main political gatekeeper: ProSense got De Novo authorization in June 2024, but any review delay can push sales back by quarters.\u003c\/p\u003e\n\u003cp\u003eReimbursement is just as important, since public payers decide if cryoablation scales beyond niche use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael defense spend\u003c\/td\u003e\n\u003ctd\u003e~8% of GDP, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael GDP\u003c\/td\u003e\n\u003ctd\u003e~$540B, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA milestone\u003c\/td\u003e\n\u003ctd\u003eProSense De Novo, June 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExamines how Political, Economic, Social, Technological, Environmental, and Legal forces shape IceCure Medical Ltd’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, clear IceCure Medical PESTLE snapshot that simplifies external risk review and speeds up planning discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eConsolidates primary industry reports, clinical studies, and government data so investors can verify IceCure Medical assumptions quickly and defensibly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNASDAQ ticker ICCM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd trades on Nasdaq under ICCM, so it can tap U.S. capital markets for funding, but the stock is also pulled by biotech sentiment and rate swings. For a small-cap medtech name, liquidity and investor appetite can move fast, which can widen bid-ask spreads and raise the cost of new shares. That makes fundraising possible, but not cheap or stable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTASE listing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s TASE listing broadens its investor base in Israel and gives it dual-market access for funding. That can improve financing flexibility, but it also raises compliance and reporting costs across two exchanges. Medtech sentiment can shift fast, so share-price moves may be sharp when clinical or funding news lands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2.3m breast cases, 2022\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal breast cancer incidence reached 2.3 million cases in 2022, according to GLOBOCAN. That gives IceCure Medical Ltd a large addressable market for breast-focused minimally invasive treatment. Even a small share of these cases can drive meaningful procedure volume. The scale of demand supports faster adoption if clinical and reimbursement barriers ease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical-trial funding needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIceCure Medical Ltd must keep funding late-stage studies, regulatory work, and commercialization before broad reimbursement arrives, so cash burn can stay high even when sales are still limited. In 2025\/2026, that makes equity financing a core growth tool, not a backup. The result is ongoing pressure on liquidity and dilution risk for shareholders.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLate-stage trials need steady cash.\u003c\/li\u003e\n\u003cli\u003eReimbursement often lags spending.\u003c\/li\u003e\n\u003cli\u003eEquity funding stays central.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOutpatient cost case\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutpatient cryoablation can win on shorter procedure time, less anesthesia, and faster recovery, so the total episode cost can be lower than inpatient surgery. That matters for payers and hospitals, because lower facility use and quicker discharge improve margin and throughput in ambulatory settings. For IceCure Medical Ltd, this economic fit can help adoption where providers want more same-day care and fewer bed-day costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower total episode cost helps payer approval.\u003c\/li\u003e\n\u003cli\u003eAmbulatory workflows improve provider economics.\u003c\/li\u003e\n\u003cli\u003eShorter recovery supports same-day discharge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIceCure’s Growth Hinges on Funding, Reimbursement, and Adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s economics hinge on funding, pricing, and reimbursement. With Nasdaq and TASE access, it can raise capital, but small-cap biotech swings keep dilution risk high. GLOBOCAN put breast cancer at 2.3 million cases in 2022, so even modest adoption can matter if payers back lower-cost outpatient cryoablation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2.3 million\u003c\/td\u003e\n\u003ctd\u003eGlobal breast cancer cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNasdaq and TASE\u003c\/td\u003e\n\u003ctd\u003eFunding access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHigh cash burn\u003c\/td\u003e\n\u003ctd\u003eDilution risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eIceCure Medical Ltd PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact IceCure Medical Ltd PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2.3m breast cases, 2022\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBreast cancer stays a major global health issue, with about 2.3 million new cases in 2022. That scale keeps public awareness high and supports interest in less invasive treatment options like IceCure Medical Ltd's cryoablation systems. The WHO says cancer burden will keep rising, so demand for earlier, patient-friendly care remains strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFemale patient focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBreast cancer is the most common cancer in women worldwide, with about 2.3 million new cases and 670,000 deaths each year, so IceCure Medical Ltd speaks to a large women’s health need. Patients often balance survival, appearance, pain, and recovery, not just tumor control. That makes education and shared decision-making critical, because women who understand less invasive options may be more willing to choose treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBreast-conserving preference\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany patients prefer to avoid major surgery when breast-conserving treatment is medically safe, and that social shift supports IceCure Medical Ltd’s minimally invasive ablation approach. In early-stage breast cancer, breast-conserving surgery is already common in the U.S., and preserving tissue can matter as much as tumor control for many patients. As acceptance of less invasive cancer care rises, adoption can improve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e771m aged 65+, 2022\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe global population aged 65 and over reached about 771 million in 2022, and that group keeps growing as life expectancy rises. Cancer risk increases with age, so more older adults usually means more screening, diagnosis, and treatment demand. For IceCure Medical Ltd, this supports long-term need for minimally invasive cancer care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAging boosts cancer demand.\u003c\/li\u003e\n\u003cli\u003e771 million were 65+ in 2022.\u003c\/li\u003e\n\u003cli\u003eMore seniors can lift market growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCosmetic outcome pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCosmetic outcome pressure is strong in breast care: many patients weigh visible scars and downtime as much as clinical success. In 2025, breast cancer still affects about 1 in 8 women in the U.S., so treatments that reduce scarring and recovery time can better fit quality-of-life expectations and support faster return to work and family life.\u003c\/p\u003e\n\u003cp\u003eFor IceCure Medical Ltd, that social preference can also shape referral behavior, since physicians often favor options patients see as less invasive and more cosmetic-friendly. This can lift demand for cryoablation if it preserves appearance and shortens recovery versus surgery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower scarring can drive patient choice.\u003c\/li\u003e\n\u003cli\u003eShorter downtime supports acceptance.\u003c\/li\u003e\n\u003cli\u003eCosmetic fit can influence referrals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLess Invasive Breast Care Boosts IceCure Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSocial demand for IceCure Medical Ltd is helped by a strong preference for less invasive care, because many women weigh scarring, pain, and recovery time against tumor control. Breast cancer still affects about 1 in 8 U.S. women, and breast-conserving care remains widely accepted, so cosmetic and quality-of-life goals matter in treatment choice. Aging also supports demand: 771 million people were 65+ in 2022.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. women\u003c\/td\u003e\n\u003ctd\u003e1 in 8 face breast cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal 65+\u003c\/td\u003e\n\u003ctd\u003e771 million in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient preference\u003c\/td\u003e\n\u003ctd\u003eLess scarring, faster recovery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCryoablation freezing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s core platform uses extreme cold to freeze and kill tumor tissue, so its PESTLE edge comes from cryoablation rather than heat-based ablation. That technical split changes planning because the ice ball can be seen in real time, helping surgeons control margins and protect nearby tissue. It can also affect treatment time, tissue injury, and the types of tumors that are practical to treat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProSense platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProSense is IceCure Medical Ltd’s main commercial system, so it anchors the company’s tech stack and makes training, workflow, and accessory use more consistent. A single named platform also helps regulators and clinicians compare outcomes more cleanly; that matters in a market with over 2.3 million new breast cancer cases worldwide each year. It supports a tighter sales story and faster adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImage-guided placement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImage-guided placement is the core technical step in IceCure Medical Ltd cryoablation, because the probe must reach the lesion and stay clear of healthy tissue. Ultrasound guidance gives real-time control, and even a small placement error can weaken the freeze zone or raise tissue risk. In practice, precision drives clinical success, and that makes imaging quality a key adoption factor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMinimally invasive probes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s minimally invasive probes let physicians treat tissue through small entry points instead of open surgery, which can shorten procedures and support faster recovery. The main selling point is not just clinical effect; it is also convenience, since lower-trauma procedures are easier to schedule and often more acceptable to patients and clinics. That makes probe-based therapy a direct competitive lever against more invasive options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLess open surgery\u003c\/li\u003e\n\u003cli\u003eSmaller access points\u003c\/li\u003e\n\u003cli\u003eShorter recovery path\u003c\/li\u003e\n\u003cli\u003eCompetes on ease and outcomes\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eR\u0026amp;D-led iteration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s edge depends on R\u0026amp;D-led iteration: in medtech, engineering updates must be backed by clinical validation before adoption widens. In FY2025 and into 2026, that means keeping spend focused on product refinement and evidence generation, not just sales.\u003c\/p\u003e\n\u003cp\u003eNew indications can open fresh use cases over time, so each upgrade can matter more than a simple feature change. Sustained R\u0026amp;D is the main way IceCure Medical Ltd keeps technical leadership as rivals catch up.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical proof drives adoption.\u003c\/li\u003e\n\u003cli\u003eNew indications widen use cases.\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D protects technical leadership.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIceCure’s Precision Tech Outshines Its Small FY2025 Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s technology edge is its real-time, image-guided cryoablation system: ultrasound guidance helps place the probe and monitor the freeze zone, which is key to protecting healthy tissue. FY2025 revenue was $8.9 million, while cash and short-term deposits were $14.3 million at year-end, so R\u0026amp;D discipline still matters more than scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eImage-guided cryoablation\u003c\/td\u003e\n\u003ctd\u003ePrecision and margins\u003c\/td\u003e\n\u003ctd\u003eRevenue $8.9M; cash $14.3M\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA device rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s U.S. sales depend on strict FDA pathway compliance, and tumor-treatment devices face a high evidence bar because the agency often wants strong clinical data before clearance or approval. Review cycles can run long, and any label expansion means a new FDA review, which can delay revenue and raise trial costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU MDR compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEU device sales sit under the Medical Device Regulation, which has applied since 26 May 2021. MDR raises evidence, traceability, and post-market surveillance demands, so IceCure Medical Ltd faces higher legal and documentation costs in Europe; by 2025, many legacy devices still needed MDR-aligned clinical and technical files to stay on market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrial ethics approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s human studies need ethics committee and institutional review board approval, so trial starts can slow even when the science is ready.\u003c\/p\u003e\n\u003cp\u003eInformed consent, safety monitoring, and adverse-event reporting are mandatory, and ICE3 enrolled 200 patients, showing how strict oversight shapes evidence speed.\u003c\/p\u003e\n\u003cp\u003eThat legal load adds time and cost, but it also supports cleaner clinical data for regulators and payers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct-liability exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIceCure Medical Ltd faces high product-liability risk because cryoablation for cancer involves serious outcomes, so a single adverse event can hit trust fast. Strong labeling, operator training, and full procedure logs are key defenses; in IceCure Medical Ltd’s ICE3 study, 194 patients were treated, so every safety signal matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSerious outcomes raise claim risk\u003c\/li\u003e\n\u003cli\u003eTraining and labeling cut exposure\u003c\/li\u003e\n\u003cli\u003eOne event can hurt market trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData privacy rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s clinical and commercial work must follow GDPR in Europe and HIPAA in the U.S., because patient imaging, trial files, and device logs can contain sensitive health data. GDPR penalties can reach EUR 20 million or 4% of global turnover, and a 2023 Meta fine of EUR 1.2 billion shows how serious cross-border breaches can be. That makes secure storage, access control, and audit trails critical. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProtect imaging, trial, and device data\u003c\/li\u003e\n\u003cli\u003eControl cross-border transfers tightly\u003c\/li\u003e\n\u003cli\u003ePrepare for heavy privacy fines\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIceCure Faces Tight FDA, EU MDR, and GDPR Legal Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s legal risk is led by FDA and MDR rules: U.S. clearance can demand new clinical proof, while EU MDR has applied since 26 May 2021 and keeps raising evidence and post-market duties. Human studies need ethics approval and strict consent\/reporting, so trial starts and label changes can slow. Privacy and liability risk stay high under GDPR and product-safety laws.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal factor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU MDR\u003c\/td\u003e\n\u003ctd\u003eApplied 26 May 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR fine cap\u003c\/td\u003e\n\u003ctd\u003eEUR 20m or 4% turnover\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-temperature therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s cryoablation uses low temperature, not combustion or high heat, so its energy profile is different from many surgical tools. The main environmental load comes from power use, cold-chain logistics, and single-use consumables like probes and gas supply. That makes emissions more about transport and waste than direct heat generation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo open surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s no-open-surgery model can cut operating-room time, staff use, and anesthesia demand versus open procedures. That matters because the U.S. healthcare system drives about 8.5% of national greenhouse-gas emissions, so fewer large surgeries can help hospitals lower case-level resource use and support sustainability targets. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower OR resource use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLower OR resource use matters because shorter procedures cut anesthesia, sterilization loads, and theater time, and those inputs carry real cost and carbon footprints. In the UK, the NHS says operating theaters can account for up to 25% of a hospital’s emissions, so leaner care paths are attractive. IceCure Medical Ltd’s faster, less invasive workflow can help hospitals save time and lower waste.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDisposable medical waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIceCure Medical Ltd relies on single-use components and sterile consumables, so each procedure creates regulated medical waste that must be segregated, tracked, and treated. In the U.S., medical waste disposal often costs several dollars per pound, and regulated waste can cost 2-5 times more than ordinary trash. As procedure volumes rise, waste handling becomes a bigger cost and compliance issue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle-use parts raise waste per procedure.\u003c\/li\u003e\n\u003cli\u003eDisposal adds cost and regulatory risk.\u003c\/li\u003e\n\u003cli\u003eHigher case volume lifts waste load fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty cryogen logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s cryo systems rely on specialized cryogen supply, transport, and hardware that must stay stable through storage and handling. Liquid nitrogen stays at about -196°C, so any break in the chain can raise waste, emissions, and procedure risk. Supply resilience matters too: fewer disruptions means less spoilage and better sustainable use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialized cryogen inputs are supply-chain dependent.\u003c\/li\u003e\n\u003cli\u003eCold-chain handling adds energy and waste costs.\u003c\/li\u003e\n\u003cli\u003eResilient sourcing supports lower operational risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIceCure’s Low-Heat Cryoablation Can Cut Care Emissions and Waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIceCure Medical Ltd’s low-heat cryoablation can support hospital decarbonization, but its footprint still comes from power use, transport, and single-use waste. Healthcare drives about 8.5% of U.S. emissions, and NHS theaters can reach 25% of hospital emissions, so shorter, less invasive cases matter. Regulated medical waste can cost 2-5x ordinary trash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. healthcare emissions\u003c\/td\u003e\n\u003ctd\u003e8.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHS theater emissions\u003c\/td\u003e\n\u003ctd\u003eUp to 25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical waste cost\u003c\/td\u003e\n\u003ctd\u003e2-5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234504515849,"sku":"iccm-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/iccm-pestle-analysis.webp?v=1785721566","url":"https:\/\/dcfanalyst.com\/products\/iccm-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}